Explore the Agenda
7:00 am Check In, Morning Coffee & Light Refreshments
7:55 am Chair’s Opening Remarks
Tackling the Necessity for Bioconjugate Design & Payload Innovation to Secure the Future of ADCs as Clinically Meaningful Oncology Therapies
8:00 am Fuelling the Next Generation of ADCs: Protein Alkylation Payloads & the Broader ADC Innovation Imperative
- Highlighting the strategic need for diversified payload platforms to drive sustainable ADC pipeline growth and maintain market competitiveness
- Positioning protein alkylation as a differentiated and emerging modality within the evolving ADC payload landscape
- Showcasing the unique mechanism of action and therapeutic potential of Iksuda Therapeutics’ ProAlk™ payload
8:30 am Lonza’s GlycoConnect® Technology for Best-in-Class ADCs: Emerging Clinical Insights
- Exploring how Lonza’s GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
- Sharing clinical development insights on the rapidly expanding and advancing pipeline of Lonza’s GlycoConnect® technology-based partnered ADC assets
- Discussing technology expansion towards high-DAR and dual-payload ADCs
9:00 am Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms
- Exploring rationale for dual payload ADCs, combining synergetic efficacy of Topo1 payloads combined with diverse, alternative mechanisms to overcome patient resistance
- Spotlighting comprehensive preclinical efficacy of dual payload ADCs across in vitro and in vivo models
- Supporting promising efficacy results with preclinical pharmacology, PK/PD and safety profiles of dual cytotoxic conjugate
9:30 am Expansion of ADC R&D & Manufacturing Capabilities in a Payload-Linker CDMO
- Navigating buildout of ADC clinical manufacturing for diverse, highly potent payloads
- Exploring implementation of bioconjugation and bioanalytical capabilities within R&D
- Leveraging process and analytical characterization insights from commercial ADCs
10:00 am Morning Break & Networking
Scientific posters will be displayed all day. Use this dedicated time to meet poster authors and ask your burning questions.
Discovery
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery
Discovery
Exploring Rationale-Driven Approaches to Deliver ADC Payload & Target Differentiation
11:00 am Showcasing Tubulin Inhibitor Payload Innovation to Develop Novel ADCs & Subvert Patient Resistance to Established Mechanisms
Chief Executive Officer & Founder, Oxford BioTherapeutics
- Weighing up novel payload development through evolving existing payload classes versus pursuing novel mechanisms
- Leveraging new and advanced tools to investigate novel tubulin payload development
- Contextualising payload innovation through ADC programmes and understanding significance for nextgeneration ADC development
11:30 am Contrasting Discovery & Preclinical Head‑to‑Head Comparison of Two ADCs
Chief Scientific Officer, Pharmaron
- Pharmaron’s fully integrated ADC platform enables comprehensive discovery and preclinical characterization
- Direct comparison of SG and Dato‑DXd with pH‑sensitive and protease‑specific linkers, respectively
- Assessment of how linker‑driven payload release influences efficacy, in vitro and in vivo bystander effects, dosing, and safety
- Complete physicochemical, structural, in vitro, in vivo, DMPK, and toxicology assessment
12:00 pm Blending Chemistry & Biology ADC Design: Exploring Rationale- Driven Development of ALX2004 to Maximise Clinical Differentiation
Vice President, Antibody Technologies, ALX Oncology Holdings Inc.
- Highlighting design and selection of novel Topo1 payload, paired with anti-EFGR antibody
- Presenting preclinical performance of ALX2004 including activity with improved bystander activity and stability versus deruxtecan ADCs
- Sharing rationale and design to maximise therapeutic window and overcome toxicity class challenges
12:30 pm In-Cell Western Assays as a Tool for Potency Evaluation in ADC Drug Development
Field Application Scientist, LI-COR Biosciences
- Highlighting principles and applications of In-Cell Western assays in drug development and potency testing
- Comparing In-Cell Western assays with alternative assay formats, highlighting advantages and considerations
- Exploring practical insights, including example experiments, instrumentation, software tools, and supporting resources
12:45 pm Evaluating Tools Enabling Early De-Risking in ADC & Antibody-Based Therapy Development
Chief Scientific Officer, MI-mAbs
- Application of single-cell resolution screening to discover new high affinity antibodies
- Real-time functional screening to ensure robust, validated leads
- Comprehensive libraries of conjugates for fast-track development of new ADCs
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
1:00 pm Lunch & Learn Session Presentation Hosted By Merck
Invitation-only session. For all other attendees, lunch is provided in the exhibition area
Discovery
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery
Utilising Novel Conjugation Chemistries to Enhance ADC Properties & Widen Therapeutic Index
2:00 pm Exploring a Comparative Study of Click Handle Stability in Common Ligation Conditions to Improve ADC Experimental Design
Senior Scientist, GSK
- Discussing click chemistry approaches for ADC synthesis
- Assessing the compatibility of reagents used within click reactions with common conjugation conditions
- Discussing lessons learned to guide selection of the most optimal combination of click chemistry and conjugation to streamline ADC experimental design
2:30 pm Model-Informed Drug Discovery & Development: Accelerating ADC Design & Translation from Concept to Clinic
Senior Vice President, Head of Quantitative Systems Pharmacology, Certara
- Exploring how model-informed strategies transform ADC development from discovery through translation
- Demonstrating modelling and simulation approaches to optimise ADC design, prioritise high potential candidates, and guide smarter translation
- Understanding how an integrated, end-to-end framework strengthens trial design, reduces uncertainty, and accelerates next-generation ADC development
- Highlighting organ-on-a-chip platforms that deepen mechanistic understanding and improve prediction of human-specific drug behavior
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
3:00 pm Afternoon Break & Networking
Your final chance to network before the exhibition area closes. Make sure to enjoy the reception hosted by
3:45 pm Developing a Kinder & Gentler More Efficacious CEACAM5 ADC
- Contextualising lessons learned from the current ADC clinical development landscape and advocating for an enhanced focus on addressing tolerability to improve ADC performance and success for patients
- Pursuing less toxic ADC development to evolve dosing to be equivalent to naked antibody therapies and expand therapeutic index
- Highlighting differentiation strategy for kinder and gentler ADC development, headlined with preclinical profile of KIVU-305 against solid tumours
Showcasing Innovative ADC Design Philosophy to Elevate ADC Efficacy & Tolerability & Widen Therapeutic Index
4:15 pm CX-2051: Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC
- EpCAM is highly and uniformly expressed in CRC, but its normal tissue expression has precluded targeting EpCAM with systemic therapies
- Introducing CX-2051 as a first-in-class masked EpCAM targeted Topo1 ADC with compelling preclinical profile and early Phase I data
- CX-2051 is being rapidly advanced in the clinic in CRC with a path to expanding to other EpCAM expressing solid tumours